CAMBRIDGE, Mass., May 11, 2026
Apnimed announced multiple scientific presentations, including three oral presentations and a late-breaking poster, at the upcoming American Thoracic Society (ATS) 2026 International Conference taking place May 15-20 in Orlando, Florida. The company will present new clinical analyses from its extensive Phase 3 development program evaluating AD109, Apnimed’s lead investigational oral therapy candidate for obstructive sleep apnea (OSA). According to the company, the presentations will include pooled Phase 3 data from the SynAIRgy and LunAIRo clinical trials, representing one of the largest pharmacologic development programs conducted to date for OSA treatment. Additional analyses will explore AD109’s effects on snoring reduction, hypoxic burden improvement, and estimated cardiovascular risk reduction. Apnimed stated that the findings further support the potential of AD109 as a first-in-class once-nightly oral therapy targeting the underlying neurobiology and neuromuscular dysfunction associated with upper airway collapse in OSA patients.
Phase 3 AD109 Data Show Broad Clinical Potential in OSA
One of the company’s featured oral presentations at ATS 2026 will focus on a pooled analysis of the SynAIRgy and LunAIRo Phase 3 trials, evaluating the combination therapy aroxybutynin and atomoxetine (AD109) in patients with obstructive sleep apnea. Apnimed stated that the pooled dataset represents one of the most comprehensive clinical evaluations conducted for an oral OSA therapy candidate. The presentation will be delivered during the ATS “Breaking News: Clinical Trial Results in Pulmonary Medicine” symposium and is expected to highlight efficacy outcomes across a broad patient population with mild, moderate, and severe OSA.
Additional presentations will examine AD109’s impact on reducing snoring severity and improving hypoxic burden, a clinically important measurement linked to cardiovascular and metabolic complications associated with untreated sleep apnea. According to the company, improvements in oxygenation during sleep may translate into reductions in estimated cardiovascular risk, an area of increasing focus within sleep medicine research. Apnimed emphasized that the therapy is designed to directly address the neuromuscular causes of airway collapse rather than relying on mechanical interventions alone.
Oral Therapy Approach Aims to Simplify Sleep Apnea Treatment
Advertisement
AD109 is being developed as a potential first pharmacological treatment designed to improve nighttime oxygenation and restore upper airway stability in people living with obstructive sleep apnea. The investigational therapy combines aroxybutynin, a novel antimuscarinic agent, with atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). According to Apnimed, the once-daily bedtime pill is intended to provide a more convenient and less invasive alternative to traditional OSA treatments such as CPAP devices, oral appliances, or surgical interventions.
The company stated that many OSA patients remain untreated due to poor tolerance or limited adherence associated with current device-based therapies. By simplifying treatment administration through an oral approach, Apnimed believes AD109 could significantly expand access to therapy and improve long-term patient compliance. The company further noted that OSA remains a highly prevalent and underdiagnosed chronic disease affecting approximately 80 million people in the United States and nearly one billion individuals globally. Untreated OSA is associated with increased risks of cardiovascular disease, neurocognitive impairment, cardiometabolic dysfunction, and elevated mortality.
ATS Presentations Expand Focus Beyond Traditional Sleep Diagnostics
In addition to Phase 3 AD109 presentations, Apnimed will also showcase research focused on advanced sleep diagnostics and digital health technologies. A poster presentation scheduled during ATS 2026 will examine the use of deep learning optimization for sleep stage classification utilizing wearable-derived oxygen saturation, pulse rate, and movement data. The research highlights growing industry interest in integrating artificial intelligence and wearable sensor technologies into sleep medicine diagnostics and patient monitoring.
Apnimed stated that expanding diagnostic accessibility may play an important role in improving identification and treatment of sleep-related breathing disorders worldwide. Company leadership emphasized that the ATS presentations collectively reinforce Apnimed’s broader mission of advancing a new era of oral pharmacologic therapies capable of transforming treatment approaches for obstructive sleep apnea and related breathing disorders. With AD109 having completed two Phase 3 clinical trials, the company continues positioning itself at the forefront of emerging neurobiology-focused sleep medicine innovation..
Source: Apnimed press release
